Understanding genetic factors in inherited breast and ovarian cancer
Official title: Genomic Analysis of Inherited Breast and Ovarian Cancer
Funded at University of Washington · NIH-10940398 · Data updated 2026-11-12
This study is looking at the genes of families with a history of breast and ovarian cancer to find hidden changes in DNA that might increase their risk, with the hope of discovering new ways to prevent and treat these cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $645,196 |
| NIH project number | 1R01CA292733-01 |
| Project ID | NIH-10940398 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals from families with a strong history of breast and/or ovarian cancer who have not been able to identify causal genetic variants through existing testing.
✕Less likely to help
Patients without a family history of breast or ovarian cancer or those who have already identified causal variants may not benefit from this research.
What this research studies
This research investigates the genetic underpinnings of inherited breast and ovarian cancer by analyzing both coding and non-coding regions of DNA. It aims to identify previously hidden genetic variations that may influence the risk of these cancers in families with a history of the disease. Utilizing advanced genomic technologies such as long-read sequencing and CRISPR, the study will explore how these variations affect gene expression and contribute to cancer risk. By focusing on families with unexplained cancer predisposition, the research seeks to uncover new insights that could lead to better prevention and treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved genetic testing and personalized treatment options for individuals at risk of breast and ovarian cancer.
How similar studies have gone: Previous research has successfully identified genetic factors in breast and ovarian cancer, but this study aims to explore novel non-coding variations, making it a potentially groundbreaking approach.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: King, Mary-Claire — University of Washington
- Study coordinator: King, Mary-Claire
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.